Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar Cuts Another 150 Jobs In Wake Of Exubera; Sharpens Therapeutic Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

San Carlos, Calif., firm still shopping for new inhaled-insulin partner.

You may also be interested in...



Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis

CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.

Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis

CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.

Nektar PEG-Irinotecan Moves Into Phase II For Colorectal Cancer

By applying Nektar’s PEGylation technology to Camptosar, the drug may demonstrate more powerful and tolerable anti-tumor activity.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel